MIR630

Summary

MIR630 (microRNA 630, HGNC:32886) is a microRNA gene on chromosome 15q24.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693215 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32886
Approved symbol	MIR630
Name	microRNA 630
Location	15q24.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-630
Ensembl gene	ENSG00000283798
Ensembl biotype	miRNA
Entrez	693215
RNAcentral	URS000075A45A — miRNA, 97 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384957

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384957 — 1 exons

Exon	Start	End
ENSE00001499964	72587217	72587313

Expression profiles

Bgee: expression breadth broad, 33 present calls, max score 73.22.

Top tissues by expression

33 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	73.22	gold quality
right atrium auricular region	UBERON:0006631	70.19	gold quality
tibial artery	UBERON:0007610	68.20	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	67.69	gold quality
putamen	UBERON:0001874	65.27	gold quality
fundus of stomach	UBERON:0001160	63.98	gold quality
esophagus mucosa	UBERON:0002469	63.10	gold quality
vagina	UBERON:0000996	60.46	gold quality
right frontal lobe	UBERON:0002810	57.76	gold quality
left lobe of thyroid gland	UBERON:0001120	57.60	gold quality
omental fat pad	UBERON:0010414	57.12	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	56.98	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	56.74	gold quality
body of stomach	UBERON:0001161	56.44	gold quality
lower esophagus muscularis layer	UBERON:0035833	55.76	gold quality
body of pancreas	UBERON:0001150	54.95	gold quality
skin of abdomen	UBERON:0001416	53.82	gold quality
upper lobe of left lung	UBERON:0008952	53.46	gold quality
transverse colon	UBERON:0001157	53.18	gold quality
lung	UBERON:0002048	51.81	gold quality
thyroid gland	UBERON:0002046	51.64	gold quality
thoracic mammary gland	UBERON:0005200	51.40	gold quality
right ovary	UBERON:0002118	51.39	gold quality
skin of leg	UBERON:0001511	50.19	gold quality
minor salivary gland	UBERON:0001830	49.79	gold quality
subcutaneous adipose tissue	UBERON:0002190	49.55	gold quality
small intestine Peyer’s patch	UBERON:0003454	49.50	gold quality
tibial nerve	UBERON:0001323	48.99	gold quality
ascending aorta	UBERON:0001496	48.38	gold quality
body of uterus	UBERON:0009853	45.62	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 39)

• Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. (PMID:23675407)
• over-expression of miR-630 and its association with tumor progression in human gastric cancer (PMID:24621930)
• our findings suggest miR-630 as a key regulator of cancer cell progression in HER2 over-expressing breast cancer, through targeting of IGF1R. (PMID:24655723)
• The involvement of E2F1-dependent DROSHA activation in pri-miRNA processing under DNA damage stress will provide further insight into the regulation of miRNA biosynthesis. (PMID:24909689)
• These results confirmed the overexpression of miR-630 in human colorectal cancer and its association with tumor progression (PMID:24981248)
• The study proves for the first time that miR-630 is upregulated in a majority of clear cell renal cell carcinoma patients (PMID:25031755)
• MiR-630 promoted apoptosis by downregulation of CDC7. (PMID:25255219)
• The miR-630 expression in carcinoma tissues revealed a positive correlation with the levels of serum alpha-fetoprotein (PMID:25731670)
• Novel Epigenetic CREB-miR-630 Signaling Axis Regulates Radiosensitivity in Colorectal Cancer (PMID:26263387)
• Downregulation of miR-630 dramatically increased apoptotic cell death chemosensitivity to cisplatin and decreased the proliferation, invasion, and migration of EOC cells. (PMID:26345808)
• Data indicate metadherin (MTDH) as a direct target gene of microRNA miR-630. (PMID:26595523)
• a clear mechanistic link between hypoxia and tumor progression via upregulation of miR-630 and downregulation of Dicer. (PMID:26725326)
• These results suggest an endothelial origin of ectopic bone in early phase of traumatic heterotopic ossification and indicate that the inhibition of endothelial-mesenchymal transition by miR-630 targeting Slug plays a role in the formation of ectopic bone in heterotopic ossification. (PMID:26940839)
• these findings demonstrate, in hepatocellular carcinoma cells, miR-630 exerts its tumor-suppressor functions through the TGF-beta-miR-630-Slug axis (PMID:26993767)
• H19 inhibited E-cadherin expression and promoted cell invasion of NPC cells via the miR-630/EZH2 pathway (PMID:27040767)
• putative key mediator of vascular function and cardiovascular disease risk in children with underlying OSA and/or obesity (PMID:27163713)
• Ectopic miR-630 expression could inhibit proliferation, invasion and metastasis, whereas miR-630 knockdown induced proliferation, invasion, metastasis and EMT traits in esophageal squamous cell carcinoma. (PMID:27563011)
• The results showed an obvious increase in miR-630 expression from normal bladder to bladder urothelial carcinoma (P=0.027). Additionally, patients with higher miR-630 expression had significantly shorter disease-free survival (DFS) (P=0.043) and overall survival (OS) (P=0.038) than those with lower miR-630 expression (PMID:27752905)
• results suggest that miR-630 might be a tumor suppressor in GC cells. MiR-630 suppresses EMT by regulating FoxM1 in Gastric Cancer cells, supposedly via inactivation of the Ras/PI3K/AKT pathway (PMID:28601080)
• These results suggest that circRNA_100269 and miR-630 comprise a novel pathway that regulates proliferation of GC cells. (PMID:28657541)
• The volume of tumors in miR-630 mimics treatment increased rapidly compared with that in control group and overexpression promotes SKOV3 cell proliferation and migration. (PMID:29131262)
• these findings provide further evidence on the tumor-suppression function of miR-630 in breast cancer, and clarify BMI1 as a novel functional target gene of miR-630. (PMID:29208462)
• Inhibition of miR-630 decreased cell proliferation and enhanced the sensitivity of SKOV3-TR and SKOV3 cells to paclitaxel. (PMID:29452092)
• MiR-630 may be a potential biomarker for the prediction of tyrosine kinase inhibitors therapeutic response and outcome in patients with lung adenocarcinoma. (PMID:29507618)
• The present study demonstrated that three miRNAs (miR-548q, miR-630 and miR940) might be novel and useful biomarkers for nasopharyngeal carcinoma (NPC) detection. A two-miRNA signature (miR-548q and miR940) may be considered as a better biomarker for NPC detection with relatively high sensitivity and specificity. (PMID:30475754)
• MiR-630 inhibits papillary thyroid carcinoma cell growth, metastasis, and epithelial-mesenchymal transition by suppressing JAK2/STAT3 signaling pathway. (PMID:30964171)
• Data indicate that circMTDH.4/miR-630/astrocyte elevated gene-1 (AEG-1) axis is responsible for chemoresistance and radioresistance in non-small-cell lung cancer (NSCLC) cells. (PMID:31749230)
• Upregulation of miR-630 Induced by Oxidative Damage Resists Cell Migration Through Targeting ALCAM in Human Lens Epithelium Cells. (PMID:31869263)
• High-throughput microRNA profile in adult and pediatric primary glioblastomas: the role of miR-10b-5p and miR-630 in the tumor aggressiveness. (PMID:32888124)
• microRNA-630 Regulates Underglycosylated IgA1 Production in the Tonsils by Targeting TLR4 in IgA Nephropathy. (PMID:33324395)
• Circular RNA CircMTO1 suppressed proliferation and metastasis of osteosarcoma through miR-630/KLF6 axis. (PMID:33506896)
• CircPAG1 Inhibits the High Glucose-Induced Lens Epithelial Cell Injury by Sponging miR-630 and Upregulating EPHA2. (PMID:34011217)
• Effect of miR-630 expression on esophageal cancer cell invasion and migration. (PMID:34018619)
• Circular RNA MTO1 intercorrelates with microRNA-630, both associate with Enneking stage and/or pathological fracture as well as prognosis in osteosarcoma patients. (PMID:34545623)
• MicroRNA 630 Represses NANOG Expression through Transcriptional and Post-Transcriptional Regulation in Human Embryonal Carcinoma Cells. (PMID:35008480)
• CircCERS6 Suppresses the Development of Epithelial Ovarian Cancer Through Mediating miR-630/RASSF8. (PMID:35676548)
• HIF-3alpha-Induced miR-630 Expression Promotes Cancer Hallmarks in Cervical Cancer Cells by Forming a Positive Feedback Loop. (PMID:36277475)
• MiR-630 Promotes Radioresistance by Induction of Anti-Apoptotic Effect via Nrf2-GPX2 Molecular Axis in Head-Neck Cancer. (PMID:38132173)
• CircMAP3K4 Suppresses H2O2-Induced Human Lens Epithelial Cell Injury by miR-630/ERCC6 Axis in Age-Related Cataract. (PMID:38152055)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.